62937-45-5Relevant articles and documents
A method of refining prolinamides
-
Paragraph 0041-0042, (2017/01/12)
The invention relates to a method for refining prolinamide, which includes the following steps: (a) dissolving prolinamide coarse product in an organic solvent, wherein the prolinamide coarse product contains ammonium chloride, prolinamide hydrochloride or mixture thereof; (b) adding inorganic alkali for treatment; and (c) separating to obtain the prolinamide. The method for refining prolinamide is simple, the content and optical purity of the obtained product are high, and the method is very suitable for industrial production.
Synthesis, characterisation and in vitro cytotoxicity studies of a series of chiral platinum(II) complexes based on the 2-aminomethylpyrrolidine ligand: X-ray crystal structure of [PtCl2(R-dimepyrr)] (R-dimepyrr = N-dimethyl-2(R)-aminomethylpyrrolidine)
Diakos, Connie I.,Zhang, Mei,Beale, Philip J.,Fenton, Ronald R.,Hambley, Trevor W.
experimental part, p. 2807 - 2814 (2009/10/10)
A series of platinum(II) complexes were synthesised based on the enantiomerically pure amino acid proline. Novel synthetic pathways were developed, adapted from standard peptide chemistry, to produce the 2-aminomethylpyrrolidine (pyrr) ligand and its derivatives with differing arrangements of methyl substituents at the exocyclic amine sites. The crystal structure of [PtCl2(R-dimepyrr)] (R-dimepyrr = N,N-dimethyl-2(R)-aminomethylpyrrolidine) is reported and the five-membered ligand ring has been shown to be in an envelope conformation. Cytotoxicity studies were carried out on the ovarian cancer A2780 tumour cell line and its cisplatin-resistant variant, A2780cisR. Remarkably good activity was seen for several of the drugs when compared to cisplatin despite the addition of substantial steric bulk to the amine groups, and there was a lack of cross-resistance with cisplatin seen for some compounds.